Medical

SNMMI 2023 Annual Meeting

Poster #180

Preclinical application of novel isotopes and combination therapy with the FAP-targeted ligand PNT6555.

FRONTIER Clinical Trial in Progress

Abstract #TPS3161

FRONTIER: Phase 1 FAP Theranostic Study

25th International Symposium of Radiopharmaceutical Sciences

Poster #P-068

Method development for centralized manufacturing of 177Lu-PSMA-I&T

TAT12: 12th International Symposium on Targeted Alpha Theray

Preclinical characterization of a rapidly internalizing next generation PSMA ligand for use with Actinium-225

AACR Annual Meeting 2022

Poster #3554

Preclinical characterization of the novel Fibroblast Activation Protein (FAP) targeting ligand PNT6555 for the imaging and therapy of cancer

SNMMI 2022 Annual Meeting

Poster #490

Preclinical characterization of the novel Fibroblast Activation Protein (FAP) targeting ligand PNT6555 for the imaging and therapy of cancer

EANM Annual Congress 2022

E-Poster #EP-039

PNT2001 EANM 2022 E-Poster Summary: "Development and characterization of a next-generation 225Ac-PSMA radioligand"

ESMO Congress 2022

Poster #1400P

Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC): initial results from SPLASH

SNMMI Mid-Winter Annual Meeting 2022

Abstract #MWMA2244

Dosimetry results from the SPLASH trial: Study Evaluating Metastatic Castrate Resistant Prostate Cancer (mCRPC) Treatment Using [Lu-177]-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy After Second-Line Hormonal Treatment